InFlectis is a French-based drug discovery company, incoporated in 2013, developing first-in-class therapies for neurological rare diseases. They are in clinical development with an orally available small molecule that has the potential to extend lives or improve the quality-of-life for people suffering from ALS. They are also ready to enter in phase 2 clinical trial in Charcot-Marie-Tooth disease and preclinical proof of efficacy has been obtained in rare cerebellar ataxias.

IFB-088 is a first-in-class orally available small molecule drug candidate with a validated mechanism of action and a promising pharmacokinetic profile capable of crossing the blood brain barrier to target the central and peripheral nervous system. IFB-088 is a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR. The potential of IFB-088 lies in its ability to target different major cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.

–  Therapeutic areas: Neurological rare diseases

–  Based in: Nantes (FRANCE)

–  Employees: 1-10

–  Created in: 2013